Results 171 to 180 of about 12,220,634 (288)

Contemporary cost-analysis comparison of direct-to-consumer vs. traditional prescriptions of phosphodiesterase-5 inhibitors. [PDF]

Int J Impot Res, 2023
Schneider D, Loeb CA, Brevik A, El-Khatib F, Jenkins LC, Yafi FA.   +5 more
europepmc   +1 more source

Male Sexual and Reproductive Health in Diabetes and Obesity Pharmacotherapy: A Source‐Triangulated Counseling Map

Andrology, EarlyView.
ABSTRACT Background Drugs used for diabetes and obesity increasingly shape male sexual and reproductive counseling, but clinical studies, trial registrations, regulatory labels, and patents answer different questions. Objectives The objective is to map these sources and define what each can support when counseling men receiving metabolic drugs ...
Marek Broul, Michal Dubský, Aneta Hujová, Michaela Liegertová   +3 more
wiley   +1 more source

Evidence for the Additional Health Benefits Associated with Phosphodiesterase 5 Inhibitors when Used for Treating Erectile Dysfunction, with a Focus on Prostate Cancer Patients and Other Associated Conditions. [PDF]

World J Mens Health
Naranjo A, Hackett GI, Smith S, Stephens H, Kinnaird W, Kirby M.   +5 more
europepmc   +1 more source

Phosphodiesterase 5 inhibitors for pulmonary hypertension

International Journal of Evidence-Based Healthcare, 2019
openaire   +3 more sources

2. Phosphodiesterase-5 Inhibitors.

Nihon Naika Gakkai Zasshi, 2010
Kimura, Hiroshi, Hamada, Kaoru
openaire   +2 more sources

Rutaecarpine Improves Hyperlipidemia‐Related Erectile Dysfunction in Rats by Inhibiting Macrophage M1 Polarization‐Induced Corpus Cavernosum Fibrosis

Andrology, EarlyView.
ABSTRACT Background Hyperlipidemia‐related erectile dysfunction (HLED) responds poorly to first‐line treatments such as phosphodiesterase type 5 inhibitors (PDE5Is), emphasizing the need for alternative therapeutic strategies. Rutaecarpine (RUT), a bioactive alkaloid, exhibits significant anti‐inflammatory and anti‐fibrotic effects.
Bocheng Tu, Shiqing Zhu, Peng Hu, Xiaoyu Zhu, Jiaxin Wang, Xinqi Liu, Sen Fu, Tao Wang, Jihong Liu, Kai Cui   +9 more
wiley   +1 more source

Exploring patient preferences regarding the use of combination therapy with endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitors (PDE5i). [PDF]

JHLT Open
Kolaitis NA, Kingman M, Wilson M, Rendon GG, Lopez D, Paoli CJ, Rahman M, Martin A, McGarvey N, Lee A, Mirza S, Melendres-Groves L.   +11 more
europepmc   +1 more source

Contribution of sewage to occurrence of phosphodiesterase-5 inhibitors in natural water. [PDF]

Sci Rep, 2021
Hong Y, Lee I, Tae B, Lee W, Pan SY, Snyder SW, Kim H.   +6 more
europepmc   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) - a prospective cohort study. [PDF]

BMC Pulm Med
Kam THH, Kam KKH, Wong MKL, Yan BPY, Tan G.   +4 more
europepmc   +1 more source